Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trialMatthew D. Galsky, Enrique Grande, B. Yа. Alekseev et al.|The Lancet|2020Cited by 786
2-<sup>18</sup>fluoro-deoxy-D-glucose Positron Emission Tomography Is a Reliable Predictor for Viable Tumor in Postchemotherapy Seminoma: An Update of the Prospective Multicentric SEMPET TrialMaria De Santis|Journal of Clinical Oncology|2004Cited by 423
Bladder cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upJoaquim Bellmunt, Vesa Kataja, Anna Orsola et al.|Annals of Oncology|2011Cited by 249
EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort†J. Alfred Witjes, Donna E. Hansel, Marek Babjuk et al.|European Urology|2019Cited by 191
EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines CommitteesAlan Horwich, Donna E. Hansel, Marek Babjuk et al.|Annals of Oncology|2019Cited by 182